928134-65-0 | Osilodrostat

Chemical type

• Steroidogenesis inhibitor (small-molecule drug)

^[1]

• Steroidogenesis inhibitor

^[2]

Key properties

• Inhibits 11β-hydroxylase
• Reduces cortisol and aldosterone synthesis
• Orally active

^[1]

• Selectively inhibits CYP11B1 and CYP11B2 (enzymes in cortisol and aldosterone synthesis)
• Rapid onset and offset of action
• Reversible inhibition of steroidogenesis
• Longer half-life compared to metyrapone and ketoconazole
• Higher potency in lowering cortisol levels
• Rapid absorption with sustained efficacy up to 6.7 years
• Potential for adrenal insufficiency as a side effect, but generally reversible
• Less potent inhibition of CYP3A4
• Can increase deoxycorticosterone levels (risks of hypokalemia, hypertension, edema)
• Lesser increase in 11-deoxycortisol levels compared to metyrapone
• Less hyperandrogenic effects compared to metyrapone
• Well tolerated with minimal mineralocorticoid side effects in the reported case
• Twice-daily dosing

^[2]

• Pharmacologic treatment of refractory Cushing’s disease after pituitary surgery

^[1]

• Treatment of native cyclic Cushing syndrome
• Control of hypercortisolism in Cushing disease
• Bridge therapy when surgery is not possible
• Management of ACTH-dependent Cushing syndrome
• Treatment of exogenous cyclic Cushing syndrome (e.g., from pembrolizumab)

^[2]

Classification by use

• Chemicals used as endocrine therapeutics
• Chemicals used to inhibit steroid biosynthesis
• Chemicals used in Cushing’s disease management

^[1]

• Medications for Cushing syndrome
• Steroidogenesis inhibitors
• Pituitary/adrenal-targeted therapies

^[2]

A trustworthy factory and manufacturer

Demei Chemical Technology Co., Ltd. is a modern high-tech enterprise integrating R&D, production, and sales. The company's founder, Dr. Arron, born in April 1975, graduated from the School of Mechanical Engineering at Yanshan University and has been engaged in research in the fields of mechanical engineering and chemical synthesis for many years. The company's products focus on the chemical industry, primarily dealing in chemical raw materials and chemical production machinery and equipment. With its strong technical capabilities, advanced production equipment, and strict quality management system, the company has earned the trust of customers worldwide.

1. [Cite:1] Insulin Resistance Unveiled: Cushing's Disease in a Patient with Type 1 Diabetes Mellitus and Worsening Glycemic Control, AACE Endocrinology and Diabetes, 5 January 2026
2. [Cite:2] Osilodrostat for Cyclic Cushing Disease, AACE Endocrinology and Diabetes, Volume 13, Issue 1, January–February 2026, Pages 17-21